4dmedical Ltd (ASX:4DX) Share Price & Analysis

4DMedical is a leading medical technology company specializing in breakthrough lung imaging solutions. Leveraging its proprietary XV Technology, 4DMedical enables non-invasive, real-time, and quantitative analysis of lung function—providing unprecedented insight for clinicians diagnosing and managing respiratory disorders. Their FDA-cleared CT:VQ™ platform delivers the first and only non-contrast ventilation-perfusion imaging system, setting a new standard for evaluating conditions such as unexplained dyspnea, asthma, COPD, cystic fibrosis, and lung cancer.

The company’s software and hardware products utilize existing X-ray and CT imaging infrastructure to provide detailed, four-dimensional visualizations of how air and blood flow throughout the lungs. This unique capability allows healthcare providers to diagnose issues and monitor treatment far more precisely than traditional pulmonary tests. The platform also supports lung health screening at a population level, and dedicated solutions for restrictive or obstructive lung diseases, all without requiring invasive procedures or contrast agents.

A cornerstone of 4DMedical’s mission is advancing care for at-risk populations, such as veterans exposed to airborne hazards. Through partnerships with VA hospitals and recent legislative support, 4DMedical’s technology is enabling faster and more accurate diagnosis and management of respiratory illnesses among veterans. From research through to real-world clinical practice, 4DMedical is transforming respiratory healthcare by equipping physicians with actionable, detailed insights—ultimately improving patient outcomes and setting new benchmarks for lung function evaluation worldwide.